ByTrending Posts
Is Abbott’s Dissolving Stent Set to Transform Peripheral…
Key Highlights A Breakthrough in PAD TreatmentAbbott has received CE Mark approval in Europe for its Esprit™ BTK…
Could the Medtronic–Abbott Partnership Shift the Future of…
Key Highlights Expanding Integration Through Abbott PartnershipThe U.S. FDA has cleared Medtronic’s SmartGuard™ algorithm as an interoperable automated…
Could Medtronic’s Hugo™ Robotic System Redefine Hernia Surgery…
Key Highlights A Landmark Clinical Study for Robotic Hernia SurgeryMedtronic’s Enable Hernia Repair trial is the first Investigational…
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line…
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma…
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
Can AI-Powered Platforms from Certara, Recursion, and Charles…
Key Takeaways FDA’s New Roadmap Sparks Industry Transformation The U.S. FDA has outlined a bold strategy to make…
Will Bayer’s Backing of RedHill’s Opaganib Open New…
Key Takeaways Bayer-Supported Trial Expands Opaganib’s Potential RedHill Biopharma’s collaboration with Bayer has taken center stage with the…
Could Merck’s Oral PCSK9 Inhibitor Enlicitide Transform Cholesterol…
Key Takeaways Breakthrough in Cardiovascular Innovation Merck announced positive topline Phase 3 results for enlicitide decanoate, its investigational…
Could Johnson & Johnson’s 99.7% Acute Success in…
Key Highlights Breakthrough Clinical Data from ESC 2025Johnson & Johnson MedTech unveiled results from the VARIPURE substudy of…
Trending Posts
Latest Stories
Can Novartis’ 2025 Approvals and Launches Strengthen Its Position Across Oncology, Neuroscience, and Rare Diseases Into 2026?
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple…
Can Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology, Immunology, and MedTech Into 2026 and Beyond?
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver Disease Into 2026 and Beyond?
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025…
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth Beyond 2026?
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a…
Gallery
